Toxicogenomics: Difference between revisions
No edit summary |
m Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
'''Toxicogenomics''' is a field of [[science]] that deals with the collection, interpretation, and storage of information about [[gene]] and [[protein]] activity within particular [[Cell (biology)|cell]] or [[Tissue (biology)|tissue]] of an [[organism]] in response to [[toxin|toxic substances]]. Toxicogenomics combines [[toxicology]] with [[genomics]] or other high throughput molecular profiling technologies such as [[transcriptomics]], [[proteomics]] and [[metabolomics]]<ref>The National Academies Press: Communicating Toxicogenomics Information to Nonexperts: A Workshop Summary (2005) [http://books.nap.edu/openbook.php?record_id=11179&page=3]</ref><ref>{{cite book |title=Toxicogenomics: Principles and Applications |editor=Hamadeh HK, Afshari CA |year=2004 |publisher=Wiley-Liss |location=Hoboken, NJ |isbn=0-471-43417-5 |author=ed. by Hisham K. Hamadeh; Cynthia A. Afshari. }}<br/>{{cite journal |author=Omenn GS |title=Book Review: Toxicogenomics: Principles and Applications |journal=Environ Health Perspect. |volume=112 |issue=16 |pages=A962 |month=November |year=2004 |pmc=1247673}}</ref>. Toxicogenomics endeavors to elucidate molecular mechanisms evolved in the expression of toxicity, and to derive molecular expression patterns (i.e., molecular biomarkers) that predict toxicity or the genetic susceptibility to it. | '''Toxicogenomics''' is a field of [[science]] that deals with the collection, interpretation, and storage of information about [[gene]] and [[protein]] activity within particular [[Cell (biology)|cell]] or [[Tissue (biology)|tissue]] of an [[organism]] in response to [[toxin|toxic substances]]. Toxicogenomics combines [[toxicology]] with [[genomics]] or other high throughput molecular profiling technologies such as [[transcriptomics]], [[proteomics]] and [[metabolomics]]<ref>The National Academies Press: Communicating Toxicogenomics Information to Nonexperts: A Workshop Summary (2005) [http://books.nap.edu/openbook.php?record_id=11179&page=3]</ref><ref>{{cite book |title=Toxicogenomics: Principles and Applications |editor=Hamadeh HK, Afshari CA |year=2004 |publisher=Wiley-Liss |location=Hoboken, NJ |isbn=0-471-43417-5 |author=ed. by Hisham K. Hamadeh; Cynthia A. Afshari. }}<br/>{{cite journal |author=Omenn GS |title=Book Review: Toxicogenomics: Principles and Applications |journal=Environ Health Perspect. |volume=112 |issue=16 |pages=A962 |month=November |year=2004 |pmc=1247673}}</ref>. Toxicogenomics endeavors to elucidate molecular mechanisms evolved in the expression of toxicity, and to derive molecular expression patterns (i.e., molecular biomarkers) that predict toxicity or the genetic susceptibility to it. | ||
| Line 18: | Line 18: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
==See also== | ==See also== | ||
| Line 38: | Line 38: | ||
{{genomics-footer}} | {{genomics-footer}} | ||
[[Category:Genomics]] | [[Category:Genomics]] | ||
Latest revision as of 15:35, 6 September 2012
|
WikiDoc Resources for Toxicogenomics |
|
Articles |
|---|
|
Most recent articles on Toxicogenomics Most cited articles on Toxicogenomics |
|
Media |
|
Powerpoint slides on Toxicogenomics |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Toxicogenomics at Clinical Trials.gov Trial results on Toxicogenomics Clinical Trials on Toxicogenomics at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Toxicogenomics NICE Guidance on Toxicogenomics
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Toxicogenomics Discussion groups on Toxicogenomics Patient Handouts on Toxicogenomics Directions to Hospitals Treating Toxicogenomics Risk calculators and risk factors for Toxicogenomics
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Toxicogenomics |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Toxicogenomics is a field of science that deals with the collection, interpretation, and storage of information about gene and protein activity within particular cell or tissue of an organism in response to toxic substances. Toxicogenomics combines toxicology with genomics or other high throughput molecular profiling technologies such as transcriptomics, proteomics and metabolomics[1][2]. Toxicogenomics endeavors to elucidate molecular mechanisms evolved in the expression of toxicity, and to derive molecular expression patterns (i.e., molecular biomarkers) that predict toxicity or the genetic susceptibility to it.
This broad definition is supported by the United States Environmental Protection Agency stating that "the term "genomics" encompasses a broader scope of scientific inquiry and associated technologies than when genomics was initially considered. A genome is the sum total of all an individual organism's genes. Thus, genomics is the study of all the genes of a cell, or tissue, at the DNA (genotype), mRNA (transcriptome), or protein (proteome) levels. Genomics methodologies are expected to provide valuable insights for evaluating how environmental stressors affect cellular/tissue function and how changes in gene expression may relate to adverse effects. However, the relationships between changes in gene expression and adverse effects are unclear at this time and may likely be difficult to elucidate."[3]
The nature and complexity of the data (in volume and variability) demands highly developed processes for of automated handling and storage. The analysis usually involves a wide array of bioinformatics and statistics.[4], regularly involving classification approaches[5].
In pharmaceutical Drug discovery and development toxicogenomics is used to study adverse, i.e. toxic, effects, of pharmaceutical drugs in defined model systems in order to draw conclusions on the toxic risk to patients or the environment. Both the EPA and the U.S. Food and Drug Administration currently preclude basing regulatory decision making on genomics data alone. However, they do encourage the voluntary submission of well-documented, quality genomics data. Both agencies are considering the use of submitted data on a case-by-case basis for assessment purposes (e.g., to help elucidate mechanism of action or contribute to a weight-of-evidence approach) or for populating relevant comparative databases by encouraging parallel submissions of genomics data and traditional toxicologic test results.[6]
Public Toxicogenomics Projects
- Chemical Effects in Biological Systems (CEBS) - Project hosted by the National Institute of Environmental Health Sciences (NIEHS) building a knowledgebase of toxicology studies including study design, clinical pathology, and histopathology and toxicogenomics data.[7]
- InnoMed PredTox assessing the value of combining results from omics technologies together with the results from more conventional toxicology methods in more informed decision making in preclinical safety evaluation.[8]
- Predictive Safety Testing Consortium aiming to identify and clinically qualify safety biomarkers for regulatory use as part of the FDA's Critical Path Initiative[8]
- ToxCast program for Predicting Hazard, Characterizing Toxicity Pathways, and Prioritizing the Toxicity Testing of Environmental Chemicals at the United States Environmental Protection Agency[9]
References
- ↑ The National Academies Press: Communicating Toxicogenomics Information to Nonexperts: A Workshop Summary (2005) [1]
- ↑ ed. by Hisham K. Hamadeh; Cynthia A. Afshari. (2004). Hamadeh HK, Afshari CA, ed. Toxicogenomics: Principles and Applications. Hoboken, NJ: Wiley-Liss. ISBN 0-471-43417-5.
Omenn GS (2004). "Book Review: Toxicogenomics: Principles and Applications". Environ Health Perspect. 112 (16): A962. PMC 1247673. Unknown parameter|month=ignored (help) - ↑ EPA Interim Genomics Policy
- ↑ Mattes WB, Pettit SD, Sansone SA, Bushel PR, Waters MD (2004). "Database development in toxicogenomics: issues and efforts". Environ. Health Perspect. 112 (4): 495–505. PMC 1241904. PMID 15033600. Unknown parameter
|month=ignored (help) - ↑ Ellinger-Ziegelbauer H, Gmuender H, Bandenburg A, Ahr HJ (2008). "Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies". Mutat. Res. 637 (1–2): 23–39. doi:10.1016/j.mrfmmm.2007.06.010. PMID 17689568. Unknown parameter
|month=ignored (help) - ↑ Corvi R, Ahr HJ, Albertini S; et al. (2006). "Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use". Environ Health Perspect. 114 (3): 420–9. PMC 1392237. PMID 16507466. Unknown parameter
|month=ignored (help) - ↑ Collins BC, Clarke A, Kitteringham NR, Gallagher WM, Pennington SR (2007). "Use of proteomics for the discovery of early markers of drug toxicity". Expert Opin Drug Metab Toxicol. 3 (5): 689–704. doi:10.1517/17425225.3.5.689. PMID 17916055. Unknown parameter
|month=ignored (help) - ↑ 8.0 8.1 Mattes WB (2008). "Public consortium efforts in toxicogenomics". Methods Mol Biol. 460: 221–38. doi:10.1007/978-1-60327-048-9_11. PMID 18449490.
- ↑ Dix DJ, Houck KA, Martin MT, Richard AM, Setzer RW, Kavlock RJ (2007). "The ToxCast program for prioritizing toxicity testing of environmental chemicals". Toxicol. Sci. 95 (1): 5–12. doi:10.1093/toxsci/kfl103. PMID 16963515. Unknown parameter
|month=ignored (help)
See also
External links
- Comparative Toxicogenomics Database - a public database that integrates toxicogenomic data for chemicals, genes, and diseases from the scientific literature.
- Center for Research on Occupational and Environmental Toxicology definition by the CROET Research Centers: (Neuro)toxicogenomics and Child Health Research Center.
- InnoMed PredTox - official project website
- ToxCast - official project website